Fig. 5: Application of 3az in treatment of ADPKD. | Nature Communications

Fig. 5: Application of 3az in treatment of ADPKD.

From: Asymmetric synthesis of P-stereogenic phosphindane oxides via kinetic resolution and their biological activity

Fig. 5

a Inhibition of the MDCK cell colony formation. n = 3. p = 0.0063, Con vs 3aa; p = 0.0201, Con vs 3ay; p = 0.0002, Con vs 3az; p = 0.0265, Con vs 1a. One-way ANOVA followed by Dunnett’s post-test. b Concentration-dependent inhibition of the in vitro MDCK cyst growth. n = 3. day 6, p < 0.0001, Con vs 3az 10 μM. day 8, p = 0.0004, Con vs 3az 1 μM; p < 0.0001, Con vs 3az 10 μM. day 10, p = 0.0013, Con vs 3az 1 μM; p < 0.0001, Con vs 3az 10 μM. two-way ANOVA followed by Dunnett’s post-test. c Inhibition of the renal cyst growth in the ex vivo embryonic kidney cyst model. n = 3. P = 0.0005, Con vs 3az 10 μM. two-sided student’s t test. d Delayed renal cyst growth in vivo in a kidney specific Pkd1 knockout mouse model. n = 6. For KW/BW, p < 0.0001. For cyst area, p = 0.0389, Con vs 3az. two-sided student’s t test. Data are presented as mean ± S.E.M., *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Source data are provided as a Source Data file.

Back to article page